CD8A and neoplasm: One of ADO’s key signaling mechanisms is via interaction with adenosine receptors, a group of four G-protein-coupled receptors, most notably the A2A adenosine receptor, causing dysregulation of effector immune cell subsets (including tumor-infiltrating NK cells and CD8+ T cells), dampening their antitumor immune response [37].